Shandong Sinobioway Biomedicine (002581.SZ): Net loss of 296.149 million yuan in the first half of the year, with a narrowing loss compared to the same period last year.

Gelonghui Finance · Aug 27 09:54

Shandong Sinobioway Biomedicine (002581.SZ) announced its interim report for the first half of 2024, with a reported revenue of 0.211 billion yuan, a year-on-year increase of 0.77%; a net loss attributable to shareholders of the listed company of -29.6149 million yuan, with a narrower year-on-year loss; a non-recurring profit and loss deducted net profit attributable to shareholders of the listed company of -26.9934 million yuan; basic earnings per share of -0.0449 yuan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

未名医药(002581.SZ)：上半年净亏损2961.49万元 同比亏损收窄

Shandong Sinobioway Biomedicine (002581.SZ): Net loss of 296.149 million yuan in the first half of the year, with a narrowing loss compared to the same period last year.

Risk Disclaimer

Statement

未名医药(002581.SZ)：上半年净亏损2961.49万元同比亏损收窄